FDA’s Psychedelics Hearing Was Really a Fight Over the Label
On September 15 the FDA spent four hours listening to roughly 80 people debate how psychedelic drugs should reach patients. Federal panelists from five agencies attended. According to Psychedelic Alpha, none of them asked a single question. The argument that mattered was about the label. The label decides who can deliver these drugs, and who gets paid to.
Label language turns into staffing rules, and staffing rules turn into overhead. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The event | A Part 15 public hearing at FDA’s White Oak campus on September 15, 2026 |
| Who listened | Panelists from FDA, NIDA, the VA, SAMHSA and ARPA-H |
| The format | About 80 speakers at two minutes each, with no questions from the panel |
| FDA’s stated position | Approval could rest on about 12 weeks of efficacy plus preliminary 12-month follow-up |
| The open question | Whether psychotherapy must be part of the treatment, which shapes who can deliver it |
| Why clinics should care | Insurers build coverage rules from the label, so the label is the business model |
What FDA Put in Writing First
The hearing followed a framework paper from FDA officials in the New England Journal of Medicine on September 10. The paper is more useful than the hearing, because it contains actual positions.
On evidence, FDA wrote that approval could rest on efficacy over a clinically meaningful duration. It gave 12 weeks as an example. That comes paired with a longer-term preliminary assessment, such as continuing blinded follow-up for 12 months.
Read both halves. Some coverage reported only the 12 weeks. The agency also wants a year of follow-up data on whether patients need additional doses.
The Three Positions That Matter Most
First, dosing. FDA wrote that the optimal interval between doses, and whether repeat doses keep working, may be addressed after approval. That means clinics could launch without a settled answer on retreatment.
Second, trial design. The agency said it is open to comparators other than inert placebo that may help maintain blinding. That is the approach used in the recent ketamine trial in bipolar depression, which compared ketamine against midazolam.
Third, risk management. FDA may require a REMS, additional post-marketing studies, or both. The Spravato REMS is the obvious template, and it is already how thousands of clinics operate. Marijuana Moment summarized the full plan. Compass is already planning its psilocybin launch around Spravato sites.
Do Not Expect One Set of Rules
Psychedelic Alpha’s read is that a shared REMS covering the whole class is very unlikely, at least for now.
Former FDA staffer Lawrence Goldkind urged the agency to tailor labeling and REMS to each specific drug. Johns Hopkins researcher Eddie Jacobs recommended an initial safety floor anchored closely to the trial context.
For operators that means drug-by-drug compliance. Two approved psychedelics could carry two different monitoring and certification regimes. FDA’s July trial guidance already treated each program separately.
The Fight Over Psychotherapy
The sharpest divide was whether a therapy component should be mandatory. Lawrence Leeman of the University of New Mexico argued the intervention should be framed as psychedelic-assisted therapy.
Peter Hendricks of the University of Alabama at Birmingham disagreed. Requiring psychotherapy, he warned, would fall hardest on the people least able to find care elsewhere. He favored labels that allow flexible treatment models.
Psychologist Geoff Bathje said he was disappointed to see FDA minimize the therapeutic relationship. This dispute is not new, and the evidence under it is thin. We found as much covering how silent most psilocybin sessions actually are.
The Line Operators Should Remember
Amna Aslam of Radial made the point most relevant to anyone running a practice. Insurers build the coverage rules from the label.
Whatever the label says about therapy, monitoring and setting becomes a payer’s checklist for approving or denying a claim. A mandatory therapy component means a therapist on the claim. A narrow setting requirement means certified sites only.
That connects to public coverage, which a recent report on Medicaid and psychedelic therapy took up in detail.
Access Versus Safety, Out Loud
John Eaton of the Wounded Warrior Project said approval alone will not create access. A retired Army officer warned that big-city clinics would leave rural and disabled veterans behind, per GreenState.
Laurel Kilgour of the Psychedelic Bar Association argued an overly zealous risk mitigation framework can undermine safety. A psychiatrist who said he had treated about 200 trial participants argued psychiatrists should be at the helm.
Those positions cannot all win. The label will pick between them.
The Skeptics Had a Point Too
Amber Barnato of the Dartmouth Institute for Health Policy described the evidence as drawn from small, functionally unblinded trials. A day earlier, Definium had reported a Phase 3 result designed specifically to address that criticism.
Kevin Sabet argued psychedelics should earn approval the way any other class of drug does. He was largely alone in opposing the direction of travel.
Barnato’s point is the stronger one for clinics. Suppose approvals arrive on 12 weeks of data, with dosing settled later. The early years would then carry real uncertainty about how often patients return. Psychiatric Times described the field as divided.
What Silence From the Panel Means
A Part 15 hearing is designed to take input, not to debate it. Two-minute slots do not allow real exchange, and no panelist spoke after opening remarks.
That is not evidence the agency is ignoring the testimony. It does mean nothing said at the hearing should be read as a signal of intent. The NEJM paper is the signal.
It also fits the pattern of the past month, including SAMHSA telling states to start preparing.
The Bottom Line
FDA is signaling faster approvals with more resolved after launch. The real contest is over label language, because insurers, state boards and staffing models will all be built from it.
Clinics already running a supervised administration model are closest to whatever template emerges.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal or medical advice. No psychedelic drug discussed here has been approved by the FDA.
